Mickael Burgy1, Hélène Brossat2, Philippe Barthelemy1, Alessio Imperiale3, Annie Trinh4, Chafia Assia Hazam5, Jean-Pierre Bergerat1, Carole Mathelin6. 1. Department of Medical Oncology, Civil Hospital, Strasbourg, France. 2. Breast Diseases Center, Department of Obstetrics and Gynaecology, Hautepierre Hospital, CHRU, University Hospital Strasbourg, Strasbourg; France. 3. Department of Nuclear Medicine, Hautepierre Hospital, CHRU, University Hospital Strasbourg, Strasbourg; France. 4. Department of Cardiology, Civil Hospital, Strasbourg, France. 5. Department of Anesthesiology, Hautepierre Hospital, CHRU, University Hospital Strasbourg, Strasbourg; France. 6. Breast Diseases Center, Department of Obstetrics and Gynaecology, Hautepierre Hospital, CHRU, University Hospital Strasbourg, Strasbourg; France carole.mathelin@chru-strasbourg.fr.
Abstract
BACKGROUND: Trastuzumab is a humanized monoclonal antibody used for the treatment of HER2-positive breast cancer. Cardiotoxicity is a well-known adverse event of trastuzumab use but little has been documented regarding its use in patients with a history of cardiac disease. CASE REPORT: We describe a case in which trastuzumab treatment was administered to a 40-year-old female patient with early breast cancer after acute heart failure secondary to postoperative Takotsubo cardiomyopathy. After one year of follow-up with close monitoring by echocardiography, there have been no heart-related symptoms. Additional surgery was performed because of positive resection margins at first surgery, without complications, despite the risk of recurrence of Takotsubo cardiomyopathy. CONCLUSION: Trastuzumab can be safely administered after acute heart failure secondary to postoperative Takotsubo cardiomyopathy. Copyright
BACKGROUND:Trastuzumab is a humanized monoclonal antibody used for the treatment of HER2-positive breast cancer. Cardiotoxicity is a well-known adverse event of trastuzumab use but little has been documented regarding its use in patients with a history of cardiac disease. CASE REPORT: We describe a case in which trastuzumab treatment was administered to a 40-year-old female patient with early breast cancer after acute heart failure secondary to postoperative Takotsubo cardiomyopathy. After one year of follow-up with close monitoring by echocardiography, there have been no heart-related symptoms. Additional surgery was performed because of positive resection margins at first surgery, without complications, despite the risk of recurrence of Takotsubo cardiomyopathy. CONCLUSION:Trastuzumab can be safely administered after acute heart failure secondary to postoperative Takotsubo cardiomyopathy. Copyright
Authors: Anastasiia V Bairashevskaia; Sofiya Y Belogubova; Mikhail R Kondratiuk; Daria S Rudnova; Susanna S Sologova; Olga I Tereshkina; Esma I Avakyan Journal: Int J Cardiol Heart Vasc Date: 2022-03-07